Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 10,000
- Avg volume
- 1,534
- Day's range
- $0.73 – $0.73
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entact...
Show more
Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Noveris Health Sciences Inc. in February 2026. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 778 900 6877
- Website
- https://noveris.health
- Address
- 1075 West Georgia Street, Suite 1890, Vancouver, Canada
Latest news
No headlines yet.
